Document is current
Any future updates will be listed below
-
Authors
Sun, Xiaopeng
Axelrod, Margaret L.
Waks, Adrienne G.
Fu, Jingxin
DiLullo, Molly
Van Allen, Eliezer M.
Tolaney, Sara M.
Mittendorf, Elizabeth A.
Xu, Yaomin
Balko, Justin M.
-
Funding
Funding for this research was provided by:
U.S. Department of Defense (CDMRP BC230037, CDMRP BC230037, CDMRP BC230037, CDMRP BC230037)
National Cancer Institute (P50 CA168504, P50 CA168504, P50 CA168504, P50 CA168504, P50 CA168504, P50 CA168504)
Susan G. Komen (SAC21204)
- License Information
-
More Information
Article History
Received: 6 November 2024
Accepted: 10 June 2025
First Online: 3 July 2025
Competing interests
: J.M.B. receives research support from Genentech/Roche, Bristol Myers Squibb, and Incyte Corporation, has received consulting/expert witness fees from Novartis, and is an inventor on provisional patents regarding immunotherapy targets and biomarkers in cancer. E.V.A. receives research support from Novartis, Bristol Myers Squibb, Sanofi, and NextPoint, serves as advisor and consultant for Enara Bio, Manifold Bio, Monte Rosa, Novartis Institute for Biomedical Research, Serinus Bio, TracerDx, and is an inventor on patents filed on chromatin mutations and immunotherapy response, and methods for clinical interpretation and intermittent legal consulting on patents for Foaley & Hoag. A.G.W. receives research funding from Genentech, Gilead, Macrogenics, Merck and is a steering committee member for AMBRX, and serves as a consultant and paired speaker for AstraZeneca. All other authors declare no potential conflicts of interest.
